Treatment of Peripheral Neuropathy in Patients with Diabetes.

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

Condition:
– Diabetic Neuropathies
– Diabetes Mellitus

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.Condition: – Diabetic Neuropathies- Diabetes Mellitus Study Type: InterventionalStudy Design: Treatment Eligibility Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Criteria Inclusion Criteria:Patients must have type I or type II Diabetes Mellitus. Have been clinically diagnosed with neuropathy. Have an HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be on insulin therapy. Must be 18 years or older. Be able to visit the doctor’s office approximately 3 times over a maximum of a 6-week period to determine if you can continue in the study. Exclusion Criteria:History of significant liver problems. Have poor kidney function. Drink an excess of alcohol or abuse drugs. Have recently participated in or are currently participating in a Medical study in which you receive an experimental drug. Are a woman and are pregnant or breastfeeding, intending to become pregnant within the next 2 years, or are a woman not using an effective method of birth control.[1] Eli Lilly and CompanyFor additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559)St. Leonards, New South Wales, AustraliaCamperdown, New South Wales, AustraliaCaulfield, Victoria, AustraliaClayton, Victoria, Australia